Invasive fungal infections (IFI) with substantial mortality constitute an increasing problem among BMT patients. From 1986 to 1996 148 children underwent BMT, and are included in a retrospective analysis of the incidence, risk factors and outcome of IFI. By histopathology or culture-proven IFI (Candida, 10; Aspergillus, 8 ) was documented in 12/73 (16%) allogeneic and in 6/75 (8%) autologous BMT patients. Of these 18 patients, 15 subsequently died, and in 12 (66%) IFI was regarded as the main cause of death. In addition to the patients with documented IFI, 48 had suspected and 82 no fungal infection. Invasive candidal infections were more frequent in patients with semiquantitatively estimated abundant candidal colonization as compared with those with no colonization (18% vs 3%, P = 0.015). In the allogeneic group, 50% of those with severe (grades III-IV) aGVHD had IFI as opposed to 8% of those with no or mild aGVHD (P Ͻ 0.001). Regarding cGVHD, 57% of those with extensive cGVHD vs 5% of those with absent or limited cGVHD had IFI (P Ͻ 0.001). The dose of steroids was associated with IFI: 77% of those who received high-dose steroids (methylprednisolone 0.25-1 g/day for 5 days) vs 5% of those with conventional-dose (prednisone 2 mg/kg/day) had IFI (P Ͻ 0.001). Particularly for BMT patients at risk, new, quicker and better diagnostic tests and more effective anti-fungal agents, both for prophylaxis and treatment, are needed. Bone Marrow Transplantation (2000) 26, 999-1004.
Invasive fungal infections (IFI) have been an increasing problem in cancer patients for several decades already, especially among bone marrow transplant (BMT) patients. [1] [2] [3] Their incidence among transplant patients has been reported to be 10-20%. Candida and Aspergillus species have been the most common causative organisms. Mortality in these patients is high, varying from 60 to 95%. 1, 2, 4, 5 Prolonged neutropenia, disruption of mucosal barriers by intensive chemoradiotherapy, use of indwelling catheters and broad-spectrum antibiotics, graft-versus-host disease (GVHD) and its treatment, and older age are factors associated with IFI after BMT. 1, 6 The diagnosis of IFI is difficult, and frequently the presence of fungal infection has not been discovered until autopsy. 7 In addition, the treatment of fungal infection with amphotericin B may be ineffective even if started early.
Most previous reports have dealt with adult BMT patients whose underlying diseases, conditioning regimens, as well as incidence and severity of GVHD differ from those of pediatric patients. Children comprise a part of the study population in many previous reports, but few studies have focused on transplanted children. Benhamou et al 8 reported nine documented fungal infections among 125 children (7%) treated with high-dose chemotherapy and mainly autologous bone marrow rescue. In another study, five children out of 58 allogeneic BMT recipients (8.6%) had a confirmed deep Candida infection and they all died before engraftment. 9 The problem of fungal infections may be increasing also among pediatric BMT patients, as preparative regimens evolve and include transplants from unrelated donors and more profound immunosuppression. The current methods of treating fungal diseases are suboptimal. Identification of risk factors for fungal infections in these children is necessary and trials of diagnosis, prevention and treatment of IFI are planned.
We report our experience on invasive fungal infections in children transplanted between 1986 and 1996, including analysis of the incidence, risk factors and clinical course of the fungal infections.
Patients and methods
The study includes all patients who underwent allogeneic or autologous stem cell transplantation between 1986 and 1996 at the Hospital for Children and Adolescents, University of Helsinki, Finland. Half of the patients were both diagnosed and treated at this hospital, the others being referred for the transplantation procedure. Long-term followup of the referred patients took place both at the primary hospital and the transplant center. Data were obtained by carefully reviewing all hospital records of the transplant center and collecting information about subsequent events, such as relapse, death and autopsy, from the referring hospitals. The mean post-transplant follow-up was 5 (range 3-13) years.
Patients and donors
In total, 148 patients were recipients of either allogeneic (n = 73) or autologous (n = 75) stem cells. Donors were either siblings (n = 47), parents (n = 4) or unrelated donors (n = 23), 10 of them being 1-2 antigen mismatch. Two allogeneic patients were transplanted twice due to nonengraftment, and 10 patients underwent a double autologous transplant program as planned. Each patient is presented once in the following analyses unless otherwise stated. The patients underwent several different preparative regimens, with or without fractionated TBI, depending on the underlying disease and response to conventional chemotherapy. 10 Use of unrelated donors started in 1992. No grafts were T cell depleted. The main pretransplant characteristics are given in Table 1 .
GVHD prophylaxis and therapy
GVHD prophylaxis consisted of short MTX (days 1, 3, 5, 8 and 11) and cyclosporine (CYA) for 6-12 months. Acute GVHD (aGVHD) was graded I to IV, and chronic GVHD (cGVHD) as limited or extensive according to established criteria. Prednisolone (2 mg/kg/day) was started for grade II (gut or liver) or grade III (skin) aGVHD and a high-dose a Per transplant procedure. SAA = severe aplastic anemia; Cy = cyclophosphamide; Ara-C = cytosine arabinoside; VMP = etoposide, melphalan, cisplatin; Bu = busulphan; L-PAM = melphalan; PBSC = peripheral blood stem cells.
5-day pulse methylprednisolone (0.25-1 g/day in divided doses) for grades III-IV aGVHD and in some cases for extensive cGVHD, combined with antilymphocyte globulin in five patients. In addition to CYA and prednisolone, azathioprine (n = 10) and thalidomide (n = 4) were used for extensive cGVHD.
Supportive care
Use of myeloid growth factors was started in 1988, and subsequently all patients, except those with myeloid malignancies, received either G-CSF (78 transplants) or GM-CSF (11 transplants) starting on day +1 post transplant and continuing until neutrophil recovery (Ͼ 500 × 10 6 /l) with a mean duration of 17.7 (s.d. 9.5) days. Patients were treated in two-door isolation rooms until neutrophil recovery. Oral nonabsorbable antifungal agents and cotrimoxazole as pneumocystis prophylaxis were administered from the start of conditioning therapy. No other routine antimicrobial therapy was used. During the study period, use of prophylactic systemic antifungal agents became common and in total 111 (70%) patients received prophylactic ketoconazole (n = 11), fluconazole (n = 64), itraconazole (n = 30), or amphotericin B (n = 6) starting around the day of transplant and continuing until neutrophils were well recovered, the mean duration being 42 (s.d. 46) days. During neutropenia (Ͻ500 × 10 6 /l), patients received empirical broad-spectrum antibacterial therapy prompted by fever Ͼ38.5°C. If the fever persisted even after modification of antibacterial therapy, antifungal therapy, usually amphotericin B (0.7 mg/kg/day), was added to the antibiotic regimen. In all, 59 patients received amphotericin B, 32 of them liposomal formulation (AmBisome; Nexstar Pharmaceuticals, Boulder, CO, USA, 1-2 mg/kg/day). The latter was chosen to avoid or prevent further deterioration in renal function. All patients received parenteral nutrition through central venous lines.
Diagnosis of fungal infections
All patients had one or two central indwelling catheters through which blood specimens for bacterial and fungal isolation were drawn daily during fever. Routine pretransplant and weekly post-transplant surveillance cultures for fungi from stool and throat were obtained until neutrophil recovery and examined using standard procedures. The amount of isolated fungi was estimated semiquantitatively and expressed as −, +, ++ and +++ by the mycological laboratory. Invasive fungal infections were documented by histopathologic evidence of tissue invasion and/or culture isolation of the causative agent, either from a sterile body fluid or biopsy material. The patients with suspected fungal infection were those empirically receiving amphotericin B for prolonged fever but without documentation of IFI (Tables 2 and 3) .
Statistical methods
All patients were included in the analysis. Categorial values were compared using the chi-square test. Continuous vari- ables were compared using unpaired two-tailed t-test. A P value of Ͻ0.05 was considered statistically significant.
Results

Fungal infections: incidence, time of diagnosis and survival
IFIs were documented in 18/148 patients (12%), in six (8%) autologous and 12 (16%) allogeneic, caused by Aspergillus spp. (n = 8) or Candida spp. (n = 10). Five patients had candidemia, and 13 had deep tissue involvement at one or more locations, in nine patients documented at autopsy only. The sites of deep-seated infections were lung (n = 10), brain (n = 5), spleen (n = 4), liver (n = 2), heart (n = 2), kidney (n = 2), and maxilla (n = 1). In addition, 48 patients had suspected fungal infection, ie prolonged fever not responding to broad-spectrum anti-bacterial treatment. They received empiric systemic antifungal medication, usually amphotericin B, for 3 to 49 (mean 12) days. The rest of the patients (n = 82) did not have any symptoms suggesting IFI and did not receive antifungal medication.
In five of the six IFI patients in the autologous transplant
Bone Marrow Transplantation group, the fungal infections were diagnosed during the first post-transplant month, in four during post-transplant neutropenia. The sixth was diagnosed at autopsy following a post-transplant relapse. Two autologous recipients were cured of IFI: one subsequently died of relapse of neuroblastoma six months post ABMT, the other is a long-term survivor currently 8 years post ABMT. The latter patient also received a kidney transplant because one kidney was totally destroyed by neuroblastoma, and the other by C. albicans (patient 18 in Figure 1 ). In the allogeneic group, only three of the 12 patients with IFI were diagnosed during the first post-transplant month and an additional six within 100 days, three while neutropenic. Three patients with extensive cGVHD were diagnosed as late as 8, 9 and 33 months post BMT. Two allogeneic recipients were cured of their fungal infection: one after a second sibling BMT undertaken 55 days after nonengraftment of the first one (patient 7), the other after extensive surgery for aspergillomas in the maxilla and liver (patient 11, Figure 1) . 11 There were six (13%) IFI in sibling graft recipients and six (23%) in non-sibling graft recipients (NS).
During the post-transplant follow-up time of 3-13 (mean 5) years, a total of 63 (43%) BMT recipients have died. Autopsy was performed in 62% (39/63). Of the 18 patients with IFI, 12 (67%) died of causes directly related to the fungal infection, and three of other causes. Of the 130 patients not with documented IFI, 14 died for reasons other than relapse. Presence of IFI was excluded in 12 of them by autopsy (Table 3) .
Role of post-transplant neutropenia
In the patients with IFI, the time from BMT to engraftment was longer. The mean time until an ANC of Ͼ200 × 10 6 /l was 21.1 vs 15.3 days (P = 0.002), until Ͼ500 × 10 6 /l 23.6 vs 19.6 days (NS) and until Ͼ1000 × 10 6 /l 27 vs 25 days (NS) in patients with vs without IFI, respectively. Six BMT recipients (three autologous) experienced non-engraftment or graft failure. IFI was documented in three. Start of neutropenia also varied depending on the underlying disease and chemotherapy used. With the total duration of neutropenia taken into account the difference between the groups was even longer: The mean (± s.d.) number of days with neutrophils Ͻ500 × 10 6 /l was 44.9 (±56) days in the IFI group vs 23.6 (±25) days in the others (P = 0.008). In the patients who received myeloid growth factors, either G-or GM-CSF, (n = 90), the mean time to neutrophil recovery Ͼ500 × 10 6 /l was shorter: 16 days as compared to 25 days in those who did not receive growth factors (P Ͻ 0.001). However, use or non-use of growth factors was not associated with IFIs.
Role of fungal colonization and antifungal prophylaxis
Each BMT recipient had weekly surveillance of mucosal colonization by fungi, with a mean number of 5.2 (range 1-20) stool specimens and 5.0 (range 1-11) throat specimens examined. These cultures yielded a fungus isolate in 58% of the transplant patients on stool samples and in 43% on throat samples. In total, 23 different species of fungus were identified in the surveillance cultures. Of the 116 positive fungus isolates in stool samples (each fungus counted once per transplant procedure) the most common were C. albicans (n = 60), Geotrichum candidum (n = 20), Saccharomyces cerevisiae (n = 8), other Candida spp. (n = 8) and Aspergillus spp. (n = 6). Of the throat samples a total of 78 positive fungus isolates were made; the most frequent was C. albicans (n = 59), the others being other Candida spp. (n = 6), Aspergillus spp. (n = 4), Geotrichum candidum (n = 3), and Saccharomyces cerevisiae (n = 2).
The role of prophylactic antifungal medication was retrospectively assessed regarding Candida colonization and the incidence of IFI. In pre-BMT cultures, 25% of all BMT recipients had C. albicans in surveillance cultures taken from the throat, and 18% in those from stool. A patient was considered colonized if C. albicans was detected at least once in either sample type. Thus, before BMT, a total of 30% of the patients were colonized with C. albicans.
Additional patients had C. albicans isolated from surveillance samples collected after BMT, comprising in total 44% of the patients. The proportion of patients with Candida colonization did not differ among the patients who received prophylactic antifungal medication vs those who did not. However, a difference was found if only originally uncolonized patients were taken into account: of those who received prophylactic fluconazole 4% (2/50) became colonized with C. albicans, as opposed to 30% (17/57) of the group not taking prophylactic fluconazole (P = 0.006). The use of prophylactic antifungal medication was not associated with IFI, however.
Candida colonization as a simple qualitative finding was not associated with invasive Candida infections. However, if the semiquantitative estimate (−/+/++/+++) of fungus in the stool or throat specimens, was taken into account, an association with IFI was revealed. When patients were scored according to the individual largest quantity of C. albicans in any stool or throat specimen, 56% were negative, 14% were scored +, 9% ++ and 21% +++. An invasive Candida infection was documented in 3/88 (3%) of the uncolonized group, in 0/22 (0%) of the + group, in 1/14 (7%) of the ++ group, and in 6/33 (18%) of the +++ group (P = 0.015). This association was even stronger if only the patients uncolonized pretransplant were analyzed. On the other hand, pretransplant Candida colonization, even when quantitated, had no correlation with subsequent invasive candidal infection. The findings were similar when stool and throat samples were analyzed separately.
Aspergillus spp.were rarely isolated and even then, findings were occasional and thought to be due to contamination. Patient 9 experienced sudden death on day +38, revealed at autopsy to be due to rupture of the aorta caused by Aspergillus infection. His stool sample had contained one colony of A. fumigatus on day 18, with the other 10 surveillance samples taken from his stool or throat all being negative. No one else with invasive Aspergillus infection had Aspergillus isolated from any surveillance samples.
Role of GVHD
No evidence of acute GVHD was observed in 29 (40%) patients after allogeneic BMT. Mild aGVHD (grades I-II) was observed in 30 (41%) and severe (grades III-IV) in 14 (19%). IFIs were strongly associated with aGVHD: there were two cases in the group with no aGVHD (7%), three in the group with mild aGVHD (10%), and seven in the group with severe aGVHD (50%) (P Ͻ 0.001). Symptoms of chronic GVHD were evaluable only in the allogeneic recipients who survived past 100 days post BMT. Of these patients, 46 (70%) had no signs, 13 (19%) had limited and seven (11%) extensive cGVHD. Extensive cGVHD was a significant risk factor for IFI: four out of seven (57%) had IFI, as compared to the group with no or limited cGVHD where three (5%) had IFI (P Ͻ 0.001). One additional patient died with extensive cGVHD after 4 years of followup. Autopsy was not performed, so IFI could not be excluded. All patients who had IFI diagnosed later than 100 days post transplant had extensive cGVHD.
Role of corticosteroids
In the group of allogeneic recipients, 35 (48%) received corticosteroids for GVHD. A conventional dose (prednisone 2 mg/kg/day initially) was used in 22 patients for a mean of 198 days (range 14-657 days). A high-dose 5-day pulse (methylprednisolone 0.25-1 g/day in divided doses) followed by conventional-dose steroids was given to 13 patients with severe GVHD. The incidence of IFI was highly associated with the dose of steroids, being 77% (10/13) of patients who received high-dose steroids, compared to 5% (1/22) of those receiving conventional doses and 3% (1/38) of those on no steroid therapy (P Ͻ 0.001).
Discussion
Fungal infections remain a major obstacle in BMT patients. This is confirmed in our pediatric series where 12% of 148 children transplanted between 1986 and 1996 had invasive fungal infections documented. Of this group, only 3/18 are long-term survivors.
Despite the small patient number in this single institution study, careful documentation of patients, active invasive sampling for diagnostic purposes, high autopsy rate, thorough review of the hospital records, and long posttransplant follow-up revealed several important and novel aspects, regarding fungal infections among a pediatric transplant population. IFIs are difficult to diagnose and thus some cases probably remain undetected even after death if no autopsy is performed. In our study which also included late infections, the incidence of Aspergillus infections was 5% and of Candida infections 7% among all transplant recipients. Our incidence figures are in agreement with previous studies giving 4.5% for Aspergillus and 6.8-8.7% for Candida infections in young transplant patients. 1, 2, 4, 6, 9 The difficulty of early diagnosis of IFI was also well demonstrated in this study, as half of the cases were not documented until autopsy. Newly developed ELISA and PCR-based methods for fungal markers in serum, not available during this study, might be helpful in the future. [12] [13] [14] We cannot exclude the possibility of additional true cases of IFI among those who received empirical amphotericin due to suspected fungal infection and recovered.
Mortality from fungal infections among all our BMT recipients was 8% (12/148). This figure may not be an underestimate because only two patients who died of nonrelapse causes were not autopsied. In accordance with the 83% mortality in our study, mortality of the IFI patients has been reported to be very high, 80% to 100%, even if death is not always solely attributed to a fungal infection but due to many other additional causative factors. 6, 15 Neutropenia has been documented as a risk factor for IFI even though many IFIs, especially aspergillosis have not been diagnosed during neutropenia. 2, 15 Duration of neutropenia has often been defined as the time interval between BMT and neutrophil recovery to 500 × 10 6 /l. In our series, duration of severe post-transplant neutropenia (р200 × 10 6 /l) as well as the total duration of neutropenia below 500x10 6 /l was significantly longer among patients with IFI. Thus, when evaluating risk of fungal infection in transBone Marrow Transplantation planted patients, total duration of neutropenia, and particularly profound neutropenia, should be noted in addition to the time of neutrophil recovery to 500 × 10 6 /l. Fungal colonization has been a common finding in BMT patients as was also found in this study. 4, 16, 17 In previous studies, prophylactic anti-fungal medication has decreased fungal colonization and the incidence of IFI, but not mortality of cancer patients. 18, 19 Among our patients who were uncolonized pre-BMT, 4% of those receiving vs 30% of those not receiving prophylactic fluconazole were subsequently colonized with Candida. This observation is in agreement with previous studies. The role of surveillance cultures remains controversial. An association between positive surveillance cultures and invasive Candida infection in leukemia patients has been shown especially when colonization has been detected in multiple sites. 4, 20, 21 In previous studies quantity of fungus in the samples has not been addressed. According to our results, one cannot predict development of IFI based on pretransplant surveillance samples. Also detection of Candida in subsequent stool or throat specimens did not correlate with IFI. However, our data suggest that invasive Candida infection is more likely among those who reach high semiquantitative scores in the surveillance samples. The role of surveillance cultures should be assessed prospectively together with new mycological diagnostic methods in high-risk pediatric patients.
Conflicting results have been reported in regard to GVHD and the risk of IFI; most previous studies favor the role of aGVHD as a risk factor. 1,2,4,5,22 Also, the association of cGVHD and IFI, especially aspergillosis, has been shown in some, if not all, previous studies with mainly adult patients. 5, 20 Our results are in agreement with Jantunen and colleagues who were able to demonstrate both acute grades III-IV and chronic extensive GVHD as risk factors for post-transplant IFI. Eighteen percent of their patients had extensive cGVHD, and 39% of these had IFI. These patients were all adults with a median post-BMT follow-up of 23 months and without any systemic prophylactic anti-fungal medication. 5 In our series, IFIs were clearly associated with GVHD: 50% of the patients with grades III-IV aGVHD and 57% of those with extensive cGVHD had documented IFI. One of our patients with cGVHD had aspergillosis diagnosed almost 3 years post transplant, which again emphasizes the importance of long-term follow-up. While increasing numbers of transplants use unrelated donors, the incidence of GVHD and IFI is also likely to increase in the pediatric population. Effective preventive measures are to be established.
The association between IFIs and the use of corticosteroids has been reported in previous studies but seldom correlated with steroid dose. 5, 22 The risk of aspergillosis was three-fold in those who received steroid therapy of у1 mg/kg for a minimum of 7 days, compared with patients not treated with steroids. 2 Furthermore, the risk of death was higher among those BMT patients with invasive aspergillosis who had received prednisolone exceeding 7 mg/kg during the week preceding aspergillosis infection, as compared to those with a lower prednisolone dose. 15 In our series IFIs were documented more frequently in patients who had received high-dose steroids known to promote immunoparalysis and destroy neutrophil function. This medication was used for both acute and chronic GVHD. The role of high-dose steroid therapy per se as a risk factor for IFI is thus difficult to define. It is important to note that among 22 patients who received conventional dose steroids, only one had IFI.
In conclusion, protracted severe neutropenia, abundant Candida colonization, severe acute and extensive chronic GVHD as well as high-dose steroid therapy administered for GVHD were all factors associated with IFI in this pediatric BMT series. The mortality of patients with IFI was high. Prevention, rather than treatment of fully developed IFI, would obviously be a more successful method of counteracting this problem. However, prophylactic measures currently used appear ineffective in preventing IFI. New, quicker and better diagnostic procedures and more effective anti-fungal agents, for both prophylaxis and treatment, are needed.
